Year: 2023
Type: article
Study design: Observational Study
Abstract: PURPOSE: To analyze the clinical data and prognosis of patients with World Health Organization (WHO) functional class I pulmonary arterial hypertension (PAH). METHODS: This research retrospectively analyzed the clinical data (baseline, laboratory as well as echocardiography and right heart catheterization data) of 63 class I PAH patients diagnosed and treated in the Department of Cardiology, First Affiliated Hospital of Zhengzhou University, between January 2021 and June 2022. The mean follow-up time was 10.7±6.5 months. The treatment and prognosis of the patients were analyzed. RESULTS: <0.05). The three subgroups showed no obvious differences in echocardiographic indexes (right atrial size, right ventricular size and pulmonary artery systolic pressure) and related laboratory indexes (blood routines and hepatorenal function). In terms of the targeted drug therapy for PAH, the proportion of dual-drug combination therapy was the highest (48.1%), followed by monotherapy (35%) and triple combination therapy (15.9%). Nearly half (48.7%) of CTD-PAH cases were first diagnosed in the Rheumatology and Immunology Department, and all of them were given targeted drug therapy for PAH. After a mean follow-up of 10.7±6.5 months, a total of 8 endpoint events occurred, including 3 deaths due to CTD-PAH complicated with serious complications of other organs. The 1-year survival rate for all the included PAH patients was 95.2%. CONCLUSIONS: In the era of targeted therapy, class I PAH patients in China have a high early survival rate, a high proportion of combined therapy and strong multidisciplinary attention.
Source: PubMed Central
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4324130320